★ WIDE MOAT STOCKS COMPARISON ★

Checking

Stock Comparison

Sartorius Stedim Biotech S.A. vs Elekta AB (publ)

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Sartorius Stedim Biotech S.A.

DIM · Euronext Paris

Market cap (USD)$19.4B
Gross margin (TTM)44.7%
Operating margin (TTM)18.5%
Net margin (TTM)9%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryFR
Data as of2026-05-27
Moat score
80/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Sartorius Stedim Biotech S.A.'s moat claims, evidence, and risks.

View DIM analysis

Elekta AB (publ)

EKTA B · NASDAQ Stockholm

Market cap (USD)$2.1B
Gross margin (TTM)37.4%
Operating margin (TTM)5.3%
Net margin (TTM)-3.1%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountrySE
Data as of2026-06-03
Moat score
70/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Elekta AB (publ)'s moat claims, evidence, and risks.

View EKTA B analysis

Comparison highlights

  • Moat score gap: Sartorius Stedim Biotech S.A. leads (80 / 100 vs 70 / 100 for Elekta AB (publ)).
  • Segment focus: Sartorius Stedim Biotech S.A. has 2 segments (75% in Sterile single-use bioprocessing consumables); Elekta AB (publ) has 2 segments (55.8% in Solutions).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: Sartorius Stedim Biotech S.A. has 6 moat types across 3 domains; Elekta AB (publ) has 7 across 3.

Primary market context

Sartorius Stedim Biotech S.A.

Sterile single-use bioprocessing consumables

Market

Sterile single-use bioprocessing consumables (bags, filters, fluid management components)

Geography

Global

Customer

Biopharmaceutical manufacturers and CDMOs

Role

Consumables supplier (single-use)

Revenue share

75%

Elekta AB (publ)

Solutions

Market

Radiotherapy treatment delivery systems and oncology software solutions (linacs, MR-Linacs, stereotactic radiosurgery, treatment planning & oncology information systems)

Geography

Global

Customer

Hospitals, cancer centers, and clinics (often via public/central procurement)

Role

Medical device OEM + software/platform provider

Revenue share

55.8%

Side-by-side metrics

Sartorius Stedim Biotech S.A.
Elekta AB (publ)
Ticker / Exchange
DIM - Euronext Paris
EKTA B - NASDAQ Stockholm
Market cap (USD)
$19.4B
$2.1B
Gross margin (TTM)
44.7%
37.4%
Operating margin (TTM)
18.5%
5.3%
Net margin (TTM)
9%
-3.1%
Sector
Healthcare
Healthcare
Industry
Medical - Instruments & Supplies
Medical - Instruments & Supplies
HQ country
FR
SE
Primary segment
Sterile single-use bioprocessing consumables
Solutions
Market structure
Oligopoly
Oligopoly
Market share
10%-25% (implied)
40%-44% (reported)
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
80 / 100
70 / 100
Moat domains
Demand, Supply, Legal
Supply, Legal, Demand
Last update
2026-05-27
2026-06-03

Moat coverage

Shared moat types

Installed Base ConsumablesCompliance AdvantageCapex Knowhow Scale

Sartorius Stedim Biotech S.A. strengths

Design In QualificationLearning Curve YieldSuite Bundling

Elekta AB (publ) strengths

Procurement InertiaData Workflow LockinService Field NetworkSwitching Costs General

Segment mix

Sartorius Stedim Biotech S.A. segments

Full profile >

Sterile single-use bioprocessing consumables

Oligopoly

75%

Bioprocessing equipment, systems, and software/services

Oligopoly

25%

Elekta AB (publ) segments

Full profile >

Solutions

Oligopoly

55.8%

Service

Quasi-Monopoly

44.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.